$ESPR Listened to the Morgan Stanley conference. That is one confident CEO. Sales should pick up in October/November. So far the PCSK9 drugs are doing almost $1B/year and he essentially said Nexlitol will leave those in the dust, I think he said they'll wave goodbye as they pass them by. That's a pretty solid projection that they expect to have a blockbuster drug. If just that much is true, then ESPR should be worth $4B+ or $150/share. If they have successful CVOT result, just add a few billion more, but those results are still 2+ years away. Apparently company is interested in acquiring 1-2 other opportunities. Not sure I like the sound of that, but if they're confident in the future cash flow then it's a way for them to grow longer term.
  • 6
6 Likes